Lobbying disclosures · Lobbying report
BMY: second_quarter 2026 lobbying report
Issues related to prescription drugs Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)
Follow BMY- Became public
- Jul 20, 2026, 1:59 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 11:10 AM EST
Why this is connected
Legal-name match: BRISTOL-MYERS SQUIBB COMPANY is BRISTOL MYERS SQUIBB CO (https://www.sec.gov/Archives/edgar/data/14272/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/ce793bb9-f7de-4ee0-ab86-79ed48a1b63a/","filing_uuid":"ce793bb9-f7de-4ee0-ab86-79ed48a1b63a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/ce793bb9-f7de-4ee0-ab86-79ed48a1b63a/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Tracy Spicer","dt_posted":"2026-07-20T13:59:52-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"401 9th St. NW","registrant_address_2":"Suite 720","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":72111,"url":"https://lda.gov/api/v1/registrants/72111/","house_registrant_id":35940,"name":"AVENUE SOLUTIONS","description":"Government representation","address_1":"401 9th St. NW","address_2":"Suite 720","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY TEJRAL","contact_telephone":"+1 202-347-9848","dt_updated":"2026-07-30T13:56:38.410932-04:00"},"client":{"id":71374,"url":"https://lda.gov/api/v1/clients/71374/","client_id":71374,"name":"BRISTOL-MYERS SQUIBB COMPANY","general_description":"Biopharmaceutical Company","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to prescription drugs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149107,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FUENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149107,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FUENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in BMY
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 13, 2026 · disclosed Nov 5, 2026 · Spouse
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 11, 2026$15K–$50K
Rep. Mike Kelly (R-PA-16)
Sold Bristol-Myers Squibb Company BMY
$15K–$50K · Traded May 7, 2026 · disclosed Jun 11, 2026 · Spouse
Got $3K from the company’s PAC - Feb 6, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
Sold Bristol-Myers Squibb Company BMY
$15K–$50K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jan 15, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Dec 18, 2025 · disclosed Jan 15, 2026 · Joint
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Sold Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Apr 28, 2025 · disclosed Jan 13, 2026 · filed 260 days later
Got $2K from the company’s PAC - Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Bought Bristol-Myers Squibb Company BMY
$1K–$15K · Traded Oct 23, 2024 · disclosed Jan 13, 2026 · filed 447 days later
Got $2K from the company’s PAC
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.